Landulosin (Tamsulosin Hydrochloride, Dutasteride)

Landulosin, a dual α1‑adrenergic antagonist and 5‑alpha‑reductase inhibitor, is used to manage benign prostatic hyperplasia and its associated urinary symptoms.

• Benign prostatic hyperplasia (BPH): reduces prostate size and improves urinary flow.
• Lower urinary tract symptoms (LUTS) due to BPH: alleviates urgency, frequency and nocturia.
• Prevention of acute urinary retention in men with enlarged prostate: decreases risk of sudden bladder blockage.

• Landulosin combines tamsulosin, which selectively blocks α1‑adrenergic receptors in the prostate and bladder neck, leading to relaxation of smooth muscle and improved urine flow, with dutasteride, which inhibits both type I and type II 5‑alpha‑reductase enzymes, reducing conversion of testosterone to dihydrotestosterone and thereby decreasing prostate volume over time. The dual action provides immediate symptom relief from muscle tone reduction and long‑term disease modification through hormonal suppression.

Landulosin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness or light‑headedness on standing.
• Ejaculatory dysfunction, such as reduced volume.
• Nasal congestion or runny nose.

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Priapism (prolonged erection).
• Allergic reactions including rash, swelling or angioedema.

When prescribing Landulosin, clinicians should observe several precautionary measures to ensure patient safety.

• Monitor blood pressure: orthostatic hypotension may occur, especially after first dose.
• Assess liver function: dutasteride is metabolized hepatically and may require monitoring.
• Avoid use in patients with known hypersensitivity to tamsulosin, dutasteride or any excipients.
• Caution in men scheduled for prostate surgery: drug may affect intra‑operative bleeding.
• Discuss potential sexual side effects: patients should be informed about possible ejaculatory changes.
• Store at ambient temperature: keep in original container, protect from moisture.

Landulosin can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations of both components.
• Concurrent use of other α‑blockers (e.g., doxazosin, prazosin): additive risk of hypotension.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: may enhance blood‑pressure‑lowering effects.
• Warfarin: possible alteration of INR, requiring closer coagulation monitoring.
• Rifampin or other CYP3A4 inducers: may reduce dutasteride exposure and efficacy.